India's Ranbaxy falls on media report of US FDA query on plant
MUMBAI, June 24
MUMBAI, June 24 (Reuters) - Shares of Ranbaxy Laboratories Ltd fell as much as 2.3 percent on Monday after newspaper Business Standard reported the U.S. Food and Drug Administration had raised concerns about a plant in northern India, citing unidentified sources.
Business Standard said the FDA had issued form 483 to Ranbaxy regarding its Mohali plant. That form is issued when U.S. inspectors see conditions they believe may violate U.S. rules.
A Ranbaxy spokesman declined to comment when asked if the drug maker had received the 483 form.
"We continue to make regulatory submissions from Mohali and will commercialise products from Mohali when we get approvals," he said.
The U.S. FDA was not immediately reachable for comment.
Trending On Reuters
Strategies for making the most of your donations - from how to grow the money you plan to give to how to withdraw it with minimal tax implications. Video